ArticleBMC cancer2019

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.

Martin Boegemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.